πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

Showing page 26 of 857 Β· Phase 3 first, then by program name

  1. BGB-11417, BGB-11417 placebo, BGB-11417, BGB-11417, BGB-11417, Zanubrutinib

    BEONE MEDICINES AUS PTY LTD

    relapsed or refractory mantle cell lymphoma (R/R MCL)

    phase 3 small molecule active

    1 trial

  2. BGB-11417, Zanubrutinib, BGB-11417, Venclyxto 100 mg film-coated tablets, Gazyvaro 1,000 mg concentrate for solution for infusion., BGB-11417, BGB-11417

    BEONE MEDICINES AUS PTY LTD

    Previously Untreated Chronic Lymphocytic Leukemia

    phase 3 small molecule active

    1 trial

  3. BGB-16673

    BEONE MEDICINES AUS PTY LTD

    CLL

    phase 3 small molecule active

    1 trial

  4. BGB-16673

    BEONE MEDICINES AUS PTY LTD

    Chronic Lymphocytic Leukemia

    phase 3 small molecule active

    2 trials

  5. BGB-3111

    BeiGene

    WaldenstrΓΆm's Macroglobulinemia

    phase 3 small molecule completed

    1 trial

  6. BGB-43395

    BEONE MEDICINES AUS PTY LTD

    HR+/HER2- Breast Cancer

    phase 3 small molecule active

    1 trial

  7. BGF MDI 320/14.4/9.6 ΞΌg

    AstraZeneca

    COPD (Chronic Obstructive Pulmonary Disease)

    phase 3 small molecule active

    1 trial

  8. BGF MDI 320/28.8/9.6 ΞΌg

    AstraZeneca

    Asthma

    phase 3 small molecule completed

    1 trial

  9. BGF MDI HFO 320/14.4/9.6ΞΌg

    AstraZeneca

    COPD (Chronic Obstructive Pulmonary Disease)

    phase 3 small molecule completed

    1 trial

  10. BGJ398

    BridgeBio Oncology Therapeutics

    Advanced Cholangiocarcinoma

    phase 3 small molecule terminated

    1 trial

  11. BHV-7000, Placebo for BHV-7000, BHV-7000

    Biohaven Bioscience Ireland Limited

    Idiopathic Generalized Epilepsy with Generalized Tonic-clonic Seizures

    phase 3 small molecule active

    1 trial

  12. BHV-8000, DaTSCAN 74 MBq/ml solution for injection, DaTSCAN 74 MBq/ml solution for injection, BHV-8000, Placebo for BHV-8000

    Biohaven Bioscience Ireland Limited

    Early Parkinson’s Disease

    phase 3 small molecule active

    1 trial

  13. BI 1015550, BI 1015550

    Boehringer Ingelheim

    idiopathic pulmonary fibrosis (IPF), progressive pulmonary fibrosis (PPF)

    phase 3 small molecule active

    1 trial

  14. BI 1015550, Placebo matching BI 1015550, BI 1015550

    Boehringer Ingelheim

    Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)

    phase 3 small molecule active

    1 trial

  15. BI 1015550, Placebo matching nerandomilast (BI 1015550)

    Boehringer Ingelheim

    Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD)

    phase 3 small molecule active

    1 trial

  16. BI 10773

    Boehringer Ingelheim

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial

  17. BI 1291583

    Boehringer Ingelheim

    Bronchiectasis

    phase 3 small molecule active

    1 trial

  18. BI 201335

    Boehringer Ingelheim

    Hepatitis C, Chronic

    phase 3 small molecule completed

    1 trial

  19. BI 201335

    Boehringer Ingelheim

    Hepatitis C

    phase 3 small molecule completed

    1 trial

  20. BI 456906, BI 456906, BI 456906, BI 456906, BI 456906, BI 456906, BI 456906, Placebo

    Boehringer Ingelheim

    Obesity

    phase 3 small molecule active

    1 trial

  21. BI 456906, BI 456906, BI 456906, BI 456906, BI 456906, Placebo, BI 456906, BI 456906

    Boehringer Ingelheim

    Obesity

    phase 3 small molecule active

    1 trial

  22. BI 456906, BI 456906, BI 456906, BI 456906, Placebo matching products 1 to 7 (pre-filled syringe, filling volume: 0.5 mL), BI 456906, BI 456906, BI 456906

    Boehringer Ingelheim

    Obesity

    phase 3 small molecule active

    1 trial

  23. BI 456906, Placebo, BI 456906, BI 456906, BI 456906, BI 456906, BI 456906, BI 456906

    Boehringer Ingelheim

    Obesity, Diabetes mellitus type II

    phase 3 small molecule active

    1 trial

  24. BI 695501

    Boehringer Ingelheim

    Arthritis, Rheumatoid

    phase 3 small molecule completed

    2 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources